Karen O’Hanlon Cohrt - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Karen O’Hanlon Cohrt's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Karen O’Hanlon Cohrt
Verified
Editor-in-Chief, CRISPR Medicine News
Ireland
Beats
Pets, Mental Health , Nutrition, Health , Profiles, Fitness
Content
By Karen O’Hanlon Cohrt| CRISPR Medicine News Verified Korro Bio, headquartered in Massachusetts, recently announced that it has received approval from the Australian Bellberry Human Research Ethics Committee and clearance from the Australian Therapeutic Goods Administration to initiate a Phase 1/2a clinical trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD). AATD is a rare, incurable genetic condition that increases the risk of developing severe lung and liver disease, including emphysema, cancer, and organ failure.
By Karen O’Hanlon Cohrt| CRISPR Medicine News Verified In the pursuit of a precise way to control CRISPR-mediated gene editing, scientists in the United States and China have engineered a set of inducible CRISPR-based tools that are controllable by focused ultrasound (FUS), which can penetrate tissue tens of centimetres deep and directly induce localised hyperthermia.
By Karen O’Hanlon Cohrt| CRISPR Medicine News Verified Korro Bio, headquartered in Massachusetts, recently announced that it has received approval from the Australian Bellberry Human Research Ethics Committee and clearance from the Australian Therapeutic Goods Administration to initiate a Phase 1/2a clinical trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD). AATD is a rare, incurable genetic condition that increases the risk of developing severe lung and liver disease, including emphysema, cancer, and organ failure.
Company Info
CRISPR Medicine News
CRISPR Medicine News (CMN) is a media platform dedicated to the field of genetic medicine, gene therapy, and CRISPR-based genome editing technologies. It serves as an information hub, providing in-depth interviews, news, and analyses to keep stakeholders updated on advancements in CRISPR therapeutics. CMN focuses on news reporting, expert interviews, and educational content related to CRISPR technology. It covers topics such as clinical trial progress, regulatory developments, and industry best practices. The platform targets a professional audience, including researchers, biotech and pharmaceutical professionals, regulatory experts, and healthcare providers, all of whom are engaged in the evolving landscape of CRISPR therapies.
Founded: 2019